JACC: Clinical Electrophysiology Manuscript Featuring BioSig's PURE EP System in Top Five Most Influential of 2016
(Thomson Reuters ONE) -
MINNEAPOLIS, Feb. 20, 2017 (GLOBE NEWSWIRE) -- BioSig Technologies,
Inc. (OTCQB:BSGM), a medical device company developing the PURE EP(TM) System, a
proprietary platform designed to address an unmet technology need for the $4
billion electrophysiology (EP) marketplace, announced that the manuscript
entitled, "Novel Electrophysiology Signal Recording System Enables Specific
Visualization of Purkinje Network and Other High-Frequency Signals" published in
the Journal of the American College of Cardiology (JACC): Clinical
Electrophysiology is in the top 5 most read, discussed and shared articles in
2016.
BioSig Executive Chairman, Kenneth Londoner stated, "BioSig is very honored to
have this article recognized by the Clinical Electrophysiology community. We
have paid special focus on EP signals which are difficult to detect in today's
practice; and we are committed to continuing efforts toward our goal of
improving upon diagnoses and ablation treatments for patients with complex
arrhythmias."
Please visit link to Top Read Articles in JACC 2016.
About BioSig Technologies
BioSig Technologies is a medical device company developing a proprietary
technology platform designed to improve the $4 billion electrophysiology (EP)
marketplace (www.biosigtech.com). Led by a proven management team and a veteran,
independent Board of Directors, Minneapolis-based BioSig Technologies is
preparing to commercialize its PURE EP(TM) System.
BioSig's technology has been developed to address an unmet need in a large and
growing market. The PURE EP System is a novel cardiac signal acquisition and
display system which is engineered to assist electrophysiologists in clinical
decision making during procedures to diagnose and treat patients with abnormal
heart rates and rhythms. BioSig's main goal is to deliver technology to improve
upon catheter ablation treatments for the prevalent and deadly arrhythmias,
Atrial Fibrillation and Ventricular Tachycardia.
Data from the 2016 HRI Global Opportunities in Medical Devices & Diagnostics
report shows the global Electrophysiology (EP) market revenues will grow nearly
10% annually, from currently $4 billion to approximately $6 billion by 2020 with
accompanying procedure growth close to 10% annually, from 865,000 patients in
2015 to 1,350,000 in 2020.
BioSig has partnered with Minnetronix on technology development and is working
toward FDA 510(k) clearance and CE Mark for the PURE EP System. The Company has
achieved proof of concept validation and tested its prototype at the University
of California at Los Angeles (UCLA) Cardiac Arrhythmia Center, and has performed
pre-clinical studies at Mayo Clinic in Minnesota and Mount Sinai Hospital in NY.
The company continues to perform research and development studies in the form of
an Advanced Research Program at Mayo Clinic which began in June 2016. Other
prestigious cardiac arrhythmia centers including Texas Cardiac Arrhythmia
Institute and UH Case Medical Center in Cleveland also play an important role in
the PURE EP technology.
Contact:
Investor Relations:
Brian McLaughlin
BioSig Technologies, Inc.
bmclaughlin(at)biosigtech.com
917-370-9817
or
Robert Haag
Managing Partner
IRTH Communications
BSGM(at)irthcommunications.com
866-976-4784
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: BioSig Technologies, Inc. via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 20.02.2017 - 02:00 Uhr
Sprache: Deutsch
News-ID 525121
Anzahl Zeichen: 4074
contact information:
Town:
Minneapolis
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 297 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"JACC: Clinical Electrophysiology Manuscript Featuring BioSig's PURE EP System in Top Five Most Influential of 2016"
steht unter der journalistisch-redaktionellen Verantwortung von
BioSig Technologies, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
